Kwality Pharmaceuticals

KPL•

NSE

BSE

SectorHealthcare

‌
‌
‌

₹3,351.70

+₹1,727.50(103.90%)•Past Year

Loading chart…

Company insights, generated from the most recent coverage.

Highest long-term risk (4+ years) due to developmental stage of biologics pipeline, reliance on clinical trial success, and 90% revenue dependence on out-licensing partnerships.
Read more
CDMO business limited to pharmaceutical formulations with no non-pharmaceutical or consumer healthcare capabilities, restricting addressable market expansion compared to diversified peers like Akums.
Read more
Filing engine grew 166% from 75 in FY23 to 200 in FY26, enabling rapid global regulatory coverage — single dossier from regulated markets can be leveraged across 60-70 countries.
Read more

‌
‌
‌

In the news

CDMO Showdown: Gland, Akums, and Kwality—Three Paths to Growth

Kwality Pharma raises FY27 guidance, Q1 profit up 3.2% to ₹25.7 crore

Kwality Pharmaceuticals hits 52-week high on strong Q4 results

Kwality Pharmaceuticals Q4 profit surges 74.60% to ₹25.30 crore

Company insights, generated from the most recent coverage.

Highest long-term risk (4+ years) due to developmental stage of biologics pipeline, reliance on clinical trial success, and 90% revenue dependence on out-licensing partnerships.
Read more
CDMO business limited to pharmaceutical formulations with no non-pharmaceutical or consumer healthcare capabilities, restricting addressable market expansion compared to diversified peers like Akums.
Read more
Filing engine grew 166% from 75 in FY23 to 200 in FY26, enabling rapid global regulatory coverage — single dossier from regulated markets can be leveraged across 60-70 countries.
Read more